BACKGROUND: Determination of the plateletcrit (PCT) is the most effective way to evaluate platelet mass in dogs, such as Cavalier King Charles spaniel (CKCS) dogs, with macrothrombocytopenia. The IDEXX VetAutoread hematology analyzer, which performs quantitative buffy coat (QBC) analysis, has been validated to determine platelet mass in CKCS dogs. The Advia 2120 reports a PCT, but the validity of this value has not been evaluated for dogs with macrothrombocytopenia. OBJECTIVES: The goal of this study was to validate MPV and PCT determined by the Advia 2120 in dogs, including CKCS dogs, comparing values with those obtained from QBC analysis. METHODS: Advia PCT was compared with QBC results from 43 CKCS dogs and 15 dogs of other breeds in one study. Advia PCT, platelet count, and MPV were evaluated to identify biologic patterns in 31 clinically healthy CKCS dogs and 66 dogs of 3 other breeds and to generate values used for comparisons. RESULTS: Advia PCT agreed well with QBC results in general, but had a negative bias and appeared to underestimate PCT in CKCS dogs with the lowest PCTs. Advia PCT and MPV results followed expected biologic patterns in CKCS dogs and dogs of other breeds with MPVs being highest in dogs with the lowest platelet counts. CONCLUSIONS: Advia 2120 PCT and MPV satisfactorily identified changes in platelet mass and size in CKCS dogs, but PCTs were lower than expected, especially in CKCS dogs with the lowest PCTs, when compared with QBC results.
BACKGROUND: Determination of the plateletcrit (PCT) is the most effective way to evaluate platelet mass in dogs, such as Cavalier King Charles spaniel (CKCS) dogs, with macrothrombocytopenia. The IDEXX VetAutoread hematology analyzer, which performs quantitative buffy coat (QBC) analysis, has been validated to determine platelet mass in CKCSdogs. The Advia 2120 reports a PCT, but the validity of this value has not been evaluated for dogs with macrothrombocytopenia. OBJECTIVES: The goal of this study was to validate MPV and PCT determined by the Advia 2120 in dogs, including CKCSdogs, comparing values with those obtained from QBC analysis. METHODS: Advia PCT was compared with QBC results from 43 CKCSdogs and 15 dogs of other breeds in one study. Advia PCT, platelet count, and MPV were evaluated to identify biologic patterns in 31 clinically healthy CKCSdogs and 66 dogs of 3 other breeds and to generate values used for comparisons. RESULTS: Advia PCT agreed well with QBC results in general, but had a negative bias and appeared to underestimate PCT in CKCSdogs with the lowest PCTs. Advia PCT and MPV results followed expected biologic patterns in CKCSdogs and dogs of other breeds with MPVs being highest in dogs with the lowest platelet counts. CONCLUSIONS: Advia 2120 PCT and MPV satisfactorily identified changes in platelet mass and size in CKCSdogs, but PCTs were lower than expected, especially in CKCSdogs with the lowest PCTs, when compared with QBC results.